Founded in 1976, Medicakorea has remained to achieving our own business goals and enhancing social responsibility which is the improvement of human health through using better medicine.
Its GMP approved manufacturing facility is in HyangNam Pharmaceutical Industrial Complex which is about 60Km south of Seoul.
Medicakorea focuses on research on novel drugs with short development periods and high commercial potential through strategic alliances with domestic and overseas companies.
We are investing in R&D to diversify our items.
New items development is under progress and 2024, Botulinum Toxin inj. will be launched in Korea and New anti-Obesity drug is under clinical trial phase I in Korea.
MEDICAKOREA is preparing a new drug for obesity that is being jointly developed with NEUROBIOGEN.
Phase 1 clinical trial is in progress since September 2022(Seoul national university hospital, South Korea) with new drug for obesity.
NEUROBIOGEN is korean bio venture company which is newly-developed material (Selective Reversible MAO-B Inhibitor/KDS2010) reversibly and selectively blocks the abnormal synthesis of inhibitory neurotransmitter (GABA) in reactive astrocytes, and this innovative new drug targets the cure of neurodegenerative diseases and central nervous system.
Its GMP approved manufacturing facility is in HyangNam Pharmaceutical Industrial Complex which is about 60Km south of Seoul.
Medicakorea focuses on research on novel drugs with short development periods and high commercial potential through strategic alliances with domestic and overseas companies.
We are investing in R&D to diversify our items.
New items development is under progress and 2024, Botulinum Toxin inj. will be launched in Korea and New anti-Obesity drug is under clinical trial phase I in Korea.
MEDICAKOREA is preparing a new drug for obesity that is being jointly developed with NEUROBIOGEN.
Phase 1 clinical trial is in progress since September 2022(Seoul national university hospital, South Korea) with new drug for obesity.
NEUROBIOGEN is korean bio venture company which is newly-developed material (Selective Reversible MAO-B Inhibitor/KDS2010) reversibly and selectively blocks the abnormal synthesis of inhibitory neurotransmitter (GABA) in reactive astrocytes, and this innovative new drug targets the cure of neurodegenerative diseases and central nervous system.
Focus Areas
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
